If you’ve recently been diagnosed with breast cancer, you may have heard your doctor mention something called “HER2.” It can sound technical and overwhelming at first, but understanding HER2 is an important step in making sense of your diagnosis and treatment options. HER2 stands for human epidermal growth factor receptor 2. It’s a protein found […]

Integrative oncology for breast cancer: Managing HER2 treatment side effects If you’ve been diagnosed with HER2-positive breast cancer, your treatment plan may include therapies that specifically target the HER2 protein. While these treatments are effective, they can come with side effects that can be challenging to navigate. Integrative oncology can complement your treatment plan to […]

Recent advancements have brought attention to a specific group of breast cancers called “HER2-low.” These are tumors that have some HER2 protein on their surface (classified as HER2 1+ or HER2 2+ without gene amplification) but not enough to be considered HER2-positive. Enhertu (trastuzumab deruxtecan [T-DXd]), has shown significant positive results for patients with HER2-low […]

The power of exercise after HER2-positive breast cancer If you’ve been diagnosed with HER2-positive breast cancer, your treatment plan may include targeted therapies, chemotherapy, surgery, and/or radiation.  While these treatments are often effective, they may lead to side effects that take a toll on your quality of life. New data emphasizes the critical role of […]

What you should know about Enhertu We had the honor of hosting medical oncologist Dr. Heidi Ko in our recent “Ask the Expert” webinar to discuss how HER2 (human epidermal growth factor receptor 2) influences cancer care. In this educational discussion, Dr. Ko explores why testing for HER2 is significant, the treatment options available, and […]

Safety outcomes with first-line treatment of Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd) plus Perjeta (pertuzumab) is comparable with that of standard of care treatment options in patients with HER2-positive advanced or metastatic breast cancer. These findings were derived from the phase 3 DESTINY-Breast09 trial which were shared at the 2025 ASCO Annual Meeting. The multicenter, open-label DESTINY-Breast09 […]

A recent study is aiming to understand and classify the HER2 protein levels in breast cancer, particularly those with early-stage, estrogen receptor-positive (ER-positive) breast cancer. The trial, which was a part of the 2025 American Society of Oncology (ASCO) Annual Meeting, suggests that by re-examining existing ways of interpreting HER2 levels, more patients may benefit […]

One of the most important first steps after receiving a breast cancer diagnosis is understanding one’s specific type of cancer. Recently, exciting new tools are emerging that can make this process even better: artificial intelligence (AI). In a study presented at the 2025 American Society of Oncology (ASCO) Annual Meeting by Dr. Marina De Brot, […]

What is HER2-low? Insights from Dr. Sara Hurvtiz During our recent webinar on the evolution of breast cancer testing, Dr. Sara Hurvitz of Fred Hutch Cancer Center provided a helpful explanation of HER2-low. Watch the full webinar Q: What are the latest therapies specific for HER2-low breast cancer? Is this important to know in early-stage […]

What Is HER2-Positive Metastatic Breast Cancer? HER2-positive breast cancer is a type of breast cancer that has high levels of the HER2 protein, which promotes cancer cell growth. When breast cancer is metastatic, it means the cancer has spread beyond the breast to other parts of the body, such as bones, liver, lungs, or brain. […]

Neither Outcomes4Me nor any participants in or contributors to any webinar, article or content endorses or recommends any products or services. Consult your physician regarding any treatment or therapy. Watch an exclusive “Ask the Expert” webinar: “Advancing Breast Cancer Treatment From Trials to Clinical Practice.” Featuring renowned breast oncologist Dr. Eleonora Teplinsky, Head, Breast and […]

Labcorp’s Dr. Rebecca Previs, an oncologist and recognized leader in the oncology diagnostics field, joined us for a live Q&A as part of our Ask the Expert webinar series. In this webinar, Dr. Previs discusses: Definition of HER2-low How HER2-low status impacts treatment options How personalized medicine is transforming breast cancer treatment